Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alcobra Selects Premier Research for ADHD Study | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alcobra Selects Premier Research for ADHD Study

Will conduct Phase III study of MG01CI in ADHD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alcobra Ltd. has selected Premier Research as its CRO to conduct a Phase III study of MG01CI as a potential treatment for adults with Attention Deficit Hyperactivity Disorder (ADHD).
 
“We are delighted to partner with Premier Research as we embark upon our most important clinical study to date. Premier Research has extensive knowledge and expertise regarding central nervous system (CNS) clinical trials, having conducted more than 150 CNS studies over the past five years, including numerous advanced stage ADHD trials,” said Dr. Jonathan Rubin, chief medical officer of Alcobra Ltd. “Their experience, including site selection, clinical trial design and expertise in clinical trial operations, should prove invaluable as we work diligently to navigate through the FDA approval process to seek an adult ADHD indication for MG01CI.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics